Kura Oncology has received positive analyst ratings in the last quarter, with 4 bullish and 2 somewhat bullish ratings. The average 12-month price target has increased by 16.67% from the previous average, indicating a positive outlook for the stock. This is likely to have a positive short-term impact on KURA's stock price.